SELLAS Life Sciences raises $21M in registered direct offering at premium to market

SELLAS Life Sciences Group, Inc.

Gross proceeds of ~$21M from sale of 15,849,056 units (share or pre-funded warrant + warrant) at $1.325/unit.
Warrants exercisable for 15,849,056 shares at $1.20, immediately exercisable, five-year term.
Maxim Group acted as sole placement agent; offering priced at premium to market reflecting investor demand.
Offering closed on August 1, 2024, under effective shelf registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.